1 citations,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.
June 2018 in “The Journal of Sexual Medicine” Finasteride does not negatively affect male reproductive function.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
4 citations,
February 2016 in “The Journal of urology/The journal of urology” Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
2 citations,
July 2022 in “Sexual Medicine” Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
1 citations,
October 2017 in “The Journal of Urology” Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.
October 2023 in “Georgetown medical review” Finasteride and Dutasteride can improve hair growth in male baldness but may cause temporary sexual dysfunction and possibly affect fertility.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
January 2016 in “Hair transplant forum international” Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
January 2022 in “Archivos españoles de urología” Post-finasteride syndrome is rarely linked to sexual and systemic side effects.
7 citations,
March 2019 in “Cancer Epidemiology, Biomarkers & Prevention” Finasteride use is not clearly linked to an increased risk of male breast cancer.
June 2018 in “The Journal of Sexual Medicine” Men with lower education levels are more likely to have erectile dysfunction if they have coronary artery disease.
5 citations,
March 2017 in “Journal of Dermatology” Patients and doctors find current hair loss treatments unsatisfying and believe involving patients in decisions improves results.
32 citations,
March 2020 in “Drug Design Development and Therapy” Finasteride shows promise for female hair loss, but more research needed.
15 citations,
January 2018 in “Acta dermato-venereologica” Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
November 2023 in “European heart journal” Finasteride improves heart function and balance in aging and obese male rats by reducing oxidative stress.
April 2017 in “Reactions Weekly” Finasteride may cause weak ejaculation and reduced semen volume.
9 citations,
February 2018 in “Journal of Pharmaceutical and Biomedical Analysis” Quick, selective detection of tadalafil and finasteride in human plasma developed.
1 citations,
January 2020 in “Skin appendage disorders” Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.
21 citations,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
February 2013 in “Journal of The American Academy of Dermatology” Oral propranolol successfully treated a baby's skin growth and ulceration linked to PELVIS syndrome.
February 2013 in “Journal of The American Academy of Dermatology” Most children with skin inflammation taking methotrexate had lab abnormalities, but liver issues often improved without changing the medication dose.